Status:
UNKNOWN
Neuroendocrine Tumors of Old Patients in the West of France
Lead Sponsor:
University Hospital, Brest
Collaborating Sponsors:
Novartis
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
75+ years
Brief Summary
Neuroendocrine cancer remains a poorly known entity. Comprehensive treatment is multidisciplinary involving surgery, radiological and nuclear medicine, and medical. A national network for the manageme...
Eligibility Criteria
Inclusion
- 75 years old or over at the time of diagnosis
- Patient with G1/G2/G3 neuroendocrine tumor diagnosed by pathological analysis
- Patient whose medical file was examined by RENATEN (National Network for the treatment of neuro-ENdocrine sporadic and hereditary disease Tumor) meetings or other multidisciplinary consultation meeting between 01/01/2014 and 31/12/2017
- Patient with care in private and public centers in the West of France
Exclusion
- Patient with cancer other than a neuroendocrine tumor
- Patient with a G4 neuroendocrine tumor
- Patient who has objected to the study and collection of his medical data
- Refusal of participation
Key Trial Info
Start Date :
December 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 28 2020
Estimated Enrollment :
306 Patients enrolled
Trial Details
Trial ID
NCT03749681
Start Date
December 1 2018
End Date
March 28 2020
Last Update
November 21 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609